FDG PET/CT and MRI in Monitoring Very Early Therapy Response in Patients with Glioblastoma

This pilot clinical trial studies fluordeoxyglucose (fludeoxyglucose) F-18 (FDG) positron emission tomography (PET)/computed tomography (CT) and magnetic resonance imaging (MRI) in monitoring very early therapy response in patients with glioblastoma. Diagnostic procedures, such as FDG PET/CT and MRI, may help measure a patient’s response to earlier treatment. Chemotherapy can induce very rapid changes to the tumor’s glucose consumption which can be measured with imaging. FDG PET/CT and MRI shortly after the start of therapy may help identify very early therapy response in patients with glioblastoma.

Additional locations may be listed on ClinicalTrials.gov for NCT02902757.

See trial information on ClinicalTrials.gov for a list of participating sites.

Trial PhaseNo phase specified

Trial Typediagnostic

Lead OrganizationUCLA / Jonsson Comprehensive Cancer Center

Principal InvestigatorBenjamin M. Ellingson

• Primary ID15-000409
• Secondary IDsNCI-2016-00583
• ClinicalTrials.gov IDNCT02902757